Ardelyx, Inc. (ARDX) stock
ARDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3059% below fair value
$3.09−0.03 (-0.96%)
Close on Nov 13, 2026Market cap $769.99MP/E –Yield –
Ardelyx enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Ardelyx's enterprise value was $498.00M on Nov 11, 2026, against $1.17B a year earlier. Over the last 5 years it ranged from -$53.49M to $1.98B, with a median of $881.84M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $498.00M | -57.6% |
| 2025 | Dec 31, 2025 | $1.17B | +16.1% |
| 2024 | Dec 31, 2024 | $1.01B | -20.7% |
| 2023 | Dec 29, 2023 | $1.27B | +171.1% |
| 2022 | Dec 30, 2022 | $470.01M | – |
| 2021 | Dec 31, 2021 | -$24.25M | -106.1% |
| 2020 | Dec 31, 2020 | $398.47M | +8.2% |
| 2019 | Dec 31, 2019 | $368.40M | – |
| 2018 | Dec 31, 2018 | -$75.25M | -140.8% |
| 2017 | Dec 29, 2017 | $184.23M | -58.3% |
| 2016 | Dec 30, 2016 | $441.49M | +29.4% |
| 2015 | Dec 31, 2015 | $341.26M | +44.9% |
| 2014 | Dec 31, 2014 | $235.53M | – |
See a number that looks wrong?